JP2013527242A5 - - Google Patents

Download PDF

Info

Publication number
JP2013527242A5
JP2013527242A5 JP2013513339A JP2013513339A JP2013527242A5 JP 2013527242 A5 JP2013527242 A5 JP 2013527242A5 JP 2013513339 A JP2013513339 A JP 2013513339A JP 2013513339 A JP2013513339 A JP 2013513339A JP 2013527242 A5 JP2013527242 A5 JP 2013527242A5
Authority
JP
Japan
Prior art keywords
compound
coor
group
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013513339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527242A (ja
JP5752789B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/038879 external-priority patent/WO2011153315A1/en
Publication of JP2013527242A publication Critical patent/JP2013527242A/ja
Publication of JP2013527242A5 publication Critical patent/JP2013527242A5/ja
Application granted granted Critical
Publication of JP5752789B2 publication Critical patent/JP5752789B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013513339A 2010-06-04 2011-06-02 Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体 Expired - Fee Related JP5752789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35133810P 2010-06-04 2010-06-04
US61/351,338 2010-06-04
PCT/US2011/038879 WO2011153315A1 (en) 2010-06-04 2011-06-02 Modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Publications (3)

Publication Number Publication Date
JP2013527242A JP2013527242A (ja) 2013-06-27
JP2013527242A5 true JP2013527242A5 (enExample) 2014-07-17
JP5752789B2 JP5752789B2 (ja) 2015-07-22

Family

ID=44627236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513339A Expired - Fee Related JP5752789B2 (ja) 2010-06-04 2011-06-02 Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体

Country Status (12)

Country Link
US (1) US8754068B2 (enExample)
EP (1) EP2576585B8 (enExample)
JP (1) JP5752789B2 (enExample)
CN (1) CN103038245B (enExample)
AR (1) AR081637A1 (enExample)
BR (1) BR112012030818A2 (enExample)
CA (1) CA2801487C (enExample)
EA (1) EA022393B1 (enExample)
ES (1) ES2612452T3 (enExample)
MX (1) MX2012013703A (enExample)
TW (1) TW201201793A (enExample)
WO (1) WO2011153315A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
CA2800109C (en) 2010-05-20 2020-06-30 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
MY162186A (en) * 2011-01-31 2017-05-31 Viiv Healthcare Uk (No 4) Ltd C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
PT2670764E (pt) * 2011-01-31 2015-11-20 Bristol Myers Squibb Co C-28 aminas de derivados de ácido betulínico c-3 modificado como inibidores de maturação de vih
CN106822153B (zh) 2011-06-06 2019-12-17 爱荷华大学研究基金会 用于抑制肌萎缩的方法
BR112014006559A2 (pt) 2011-09-21 2017-03-28 Bristol Myers Squibb Co derivados do ácido betulínico com atividade antiviral
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
BR112015018491A2 (pt) * 2013-02-06 2017-07-18 Bristol Myers Squibb Co triterpenoides c-19-modificados com atividade inibidora de maturação de hiv
BR112015019590A2 (pt) 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
UY36070A (es) 2014-04-11 2015-10-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Triterpenoides con actividad inhibidora de la maduración de hiv
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
AU2015346303B2 (en) * 2014-11-14 2018-03-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
AU2015346314B2 (en) * 2014-11-14 2018-04-12 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
WO2016077569A1 (en) 2014-11-14 2016-05-19 Bristol-Myers Squibb Company C17-aryl substituted betulinic acid analogs
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
CA2993753A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
KR20180028535A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
WO2017051355A1 (en) 2015-09-24 2017-03-30 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
US20190023733A1 (en) 2016-01-20 2019-01-24 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
ES2836402T3 (es) 2016-06-30 2021-06-25 Viiv Healthcare Uk No 5 Ltd Derivados de azadecalina como inhibidores de la replicación del virus de inmunodeficiencia humana
JP2019519571A (ja) * 2016-06-30 2019-07-11 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製のアザ置換阻害剤
EP3478703A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
PT3784349T (pt) 2018-04-24 2024-01-22 Viiv Healthcare Uk No 5 Ltd Compostos com atividade inibidora de maturação do hiv
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
WO1999045025A1 (en) 1998-03-02 1999-09-10 The University Of North Carolina At Chapel Hill Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20040131629A1 (en) * 2002-09-26 2004-07-08 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
CA2515384C (en) * 2003-02-11 2012-04-17 Novelix Pharmaceuticals, Inc. Medicament for inhibiting tumour growth
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
US20060019934A1 (en) * 2004-05-20 2006-01-26 Saxena Brij B Anti-HIV-1 activity of betulinol derivatives
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
JP2009527563A (ja) * 2006-02-21 2009-07-30 アキリオン ファーマシューティカルズ,インコーポレーテッド ウイルス感染症を治療するのに有用な置換タラキサスタン
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008115281A2 (en) * 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
US20090062243A1 (en) * 2007-08-03 2009-03-05 Advanced Life Sciences, Inc. Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof
WO2009042166A1 (en) 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規17βルパン誘導体
WO2009114083A2 (en) 2008-03-03 2009-09-17 Panacos Pharmaceuticals, Inc. Determinants of antiviral response
EP2271658B1 (en) * 2008-04-18 2016-11-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
SG182769A1 (en) * 2010-02-11 2012-09-27 Glaxosmithkline Llc Derivatives of betulin

Similar Documents

Publication Publication Date Title
JP2013527242A5 (enExample)
JP2013527243A5 (enExample)
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
JP2014507422A5 (enExample)
JP2013510124A5 (enExample)
JP2009507896A5 (enExample)
EA201992082A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
HRP20171512T1 (hr) Derivati betulina
RU2012146777A (ru) Макроциклические ингибиторы интегразы
JP2013542247A5 (enExample)
SI2935307T1 (en) Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures
JP2014508753A5 (enExample)
JP2013518107A5 (enExample)
ME02666B (me) Cefalosporin sa kateholskom grupom
JP2017501205A5 (enExample)
ME02400B (me) Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
AR077435A1 (es) Composiciones dermatologicas de antagonistas del receptor dp2 y uso
HRP20210813T1 (hr) Piridinonpiridinilni spojevi supstituirani s metil/fluorpiridinilmetoksi i piridinonpiridinilni spojevi supstituirani s fluorpirimidinilmetoksi
SI3024819T1 (en) Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B
JP2016530259A5 (enExample)
JP2010077141A5 (enExample)
HRP20151000T1 (hr) Antivirusni spojevi
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
JP2013507423A5 (enExample)
ECSP13012812A (es) Formulaciones inmunosupresoras